Search Results - "BLAAKAER, J."

Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer? by Lydiksen, L, Jensen-Fangel, S, Blaakaer, J

“…Abstract Objective The aims of this study are to investigate the actual time from primary surgery for epithelial ovarian cancer (OC) to initiation of…”
Get full text

Hoping for the best, preparing for the worst: the lived experiences of women undergoing ovarian cancer surgery by SEIBAEK, L., PETERSEN, L.K., BLAAKAER, J., HOUNSGAARD, L.

“…SEIBAEK L., PETERSEN L.K., BLAAKAER J. & HOUNSGAARD L. (2012) European Journal of Cancer Care21, 360–371 Hoping for the best, preparing for the worst: the…”
Get full text

Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder by Mattiasson, A., Blaakaer, J., Høye, K., Wein, A.J.

“…OBJECTIVES To compare the efficacy of tolterodine plus simplified bladder training (BT) with tolterodine alone in patients with an overactive bladder. PATIENTS…”
Get full text

Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors by Begum, F.D, Høgdall, E, Kjaer, S.K, Blaakaer, J, Christensen, I.J, Christensen, L, Høgdall, C

“…Abstract Objectives To improve the poor survival in ovarian cancer (OC) patients, the research has been focused on new OC markers. One aim is to find markers…”
Get full text

Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer by Quaye, L, Song, H, Ramus, S J, Gentry-Maharaj, A, Høgdall, E, DiCioccio, R A, McGuire, V, Wu, A H, Van Den Berg, D J, Pike, M C, Wozniak, E, Doherty, J A, Rossing, M A, Ness, R B, Moysich, K B, Høgdall, C, Blaakaer, J, Easton, D F, Ponder, B A J, Jacobs, I J, Menon, U, Whittemore, A S, Krüger-Kjaer, S, Pearce, C L, Pharoah, P D P, Gayther, S A

“…Low–moderate risk alleles that are relatively common in the population may explain a significant proportion of the excess familial risk of ovarian cancer (OC)…”
Get full text

Low attendance by non-native women to human papillomavirus vaccination and cervical cancer screening – A Danish nationwide register-based cohort study by Badre-Esfahani, S., Larsen, MB, Seibæk, L., Petersen, LK, Blaakær, J., Andersen, B.

“…Cervical cancer is preventable through human papillomavirus vaccination and cervical cancer screening. However, possibly due to systemic, individual (e.g. low…”
Get full text

Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer by Faber, M. T., Jensen, A., Frederiksen, K., Glud, E., Høgdall, E., Høgdall, C., Blaakær, J., Kjær, S. K.

“…Purpose: Oral contraceptive use decreases the risk of ovarian cancer, but no previous studies have assessed the impact of cumulative intake of estrogen and…”
Get full text

Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer by QUAYE, L, SONG, H, WOZNIAK, E, DOHERTY, J. A, ROSSING, M. A, NESS, R. B, MOYSICH, K. B, HØGDALL, C, BLAAKAER, J, EASTON, D. F, PONDER, Baj, JACOBS, I. J, RAMUS, S. J, MENON, U, WHITTEMORE, A. S, KRÜGER-KJAER, S, PEARCE, C. L, PHAROAH, Pdp, GAYTHER, S. A, GENTRY-MAHARAJ, A, HØGDALL, E, DICIOCCIO, R. A, MCGUIRE, V, WU, A. H, VAN DEN BERG, D. J, PIKE, M. C

Get full text

Influence of Prior Psychiatric Disorders on the Treatment Course of Gynaecological Cancer – A Nationwide Cohort Study by Iachina, M., Ljungdalh, P.M., Sørensen, R.G., Kaerlev, L., Blaakær, J., Trosko, O., Qvist, N., Nørgård, B.M.

“…To examine the influence of pre-existing psychiatric disorder on the choice of treatment in patients with gynaecological cancer. The analyses were based on all…”
Get full text

Expanding the upper age limit for cervical cancer screening: a protocol for a nationwide non-randomised intervention study by Tranberg, Mette, Petersen, Lone Kjeld, Elfström, Klara Miriam, Hammer, Anne, Blaakær, Jan, Bennetsen, Mary Holten, Jensen, Jørgen Skov, Andersen, Berit

“…IntroductionCervical cancer screening ceases between the ages of 60 and 65 in most countries. Yet, a relatively high proportion of cervical cancers are…”
Get full text

PIN50 - COST-EFFECTIVENESS OF GENDER-NEUTRAL NINE-VALENT HPV VACCINATION IN DENMARK by Olsen, J., le Fevre, T., Blaakaer, J.

Get full text

Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer by Glud, Eva, Kjaer, Susanne K, Thomsen, Birthe L, Høgdall, Claus, Christensen, Lise, Høgdall, Estrid, Bock, Johannes E, Blaakaer, Jan

“…The association between menopausal hormone therapy (HT) and risk of ovarian cancer is as yet equivocal, and the effect of estrogen and estrogen-progestogen…”
Get more information

Value of a catch-up HPV test in women aged 65 and above: A Danish population-based nonrandomized intervention study by Tranberg, Mette, Petersen, Lone Kjeld, Hammer, Anne, Elfström, Miriam, Blaakær, Jan, Jørgensen, Susanne Fogh, Bennetsen, Mary Holten, Jensen, Jørgen Skov, Andersen, Berit

“…High-risk human papillomavirus (HPV) test is replacing cytology as the primary cervical cancer screening test due to superior sensitivity, but in most…”
Get full text

Immunoreactive inhibin concentration in blood tested under variable sampling conditions by Blaakær, Jan, Micic, Snezana, Høgdall, Claus K.

“…The stability of immunoreactive (i.r.) inhibin in blood samples drawn and handled under different conditions and at different time intervals were studied. Ten…”
Get full text

Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype by BLAAKAER, J, BAEKSTED, M, MICIC, S, ALBRECTSEN, P, RYGAARD, J, BOCK, J

“…Although many investigations have shown a correlation between elevated gonadotropin levels and ovarian tumors (the gonadotropin theory), the ovarian response…”
Get full text

Hoping for the best, preparing for the worst: the lived experiences of women undergoing ovarian cancer surgery: Hoping for the best, preparing for the worst by SEIBAEK, L., PETERSEN, L.K., BLAAKAER, J., HOUNSGAARD, L.

Get full text

Increased risk of ovarian cancer in integrin β3 Leu33Pro homozygotes by Bojesen, S E, Kjær, S K, Høgdall, E V S, Thomsen, B L, Høgdall, C K, Blaakær, J, Tybjærg-Hansen, A, Nordestgaard, B G

“…We previously demonstrated that integrin β3 Leu33Pro homozygotes have an increased risk of cancer, possibly most pronounced for ovarian cancer. We now test the…”
Get full text

Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: From the Danish MALOVA Ovarian Cancer Study by HØGDALL, Estrid V. S, CHRISTENSEN, Lise, KJAER, Susanne K, BLAAKAER, Jan, BOCK, Johannes E, GLUD, Eva, NORGAARD-PEDERSEN, Bent, HOGDALL, Claus K

“…The HER-2 (Human Epidermal Growth factor receptor-2, also known as c-erb-2/neu) protooncogene encodes a transmembrane receptor protein, M(r) 185,000. Studies…”
Get full text

The pituitary-gonadal axis in women with benign or malignant ovarian tumors by Blaakaer, J, Djursing, H, Hørding, U, Bennett, P, Toftager-Larsen, K, Bock, J E, Lebech, P E

“…The serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), estradiol, progesterone, androstenedione,…”
Get more information

Comorbidity and survival of Danish ovarian cancer patients from 2000-2011: a population-based cohort study by Grann, Anne Fia, Thomsen, Reimar Wernich, Jacobsen, Jacob Bonde, Nørgaard, Mette, Blaakær, Jan, Søgaard, Mette

“…To examine the prevalence of comorbidity among patients diagnosed with epithelial ovarian cancer in the Central Denmark Region and to study the impact of…”
Get full text